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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a genetically complex tumor type
and a major cause of cancer related mortality. Although distinct genetic alterations have been linked
to ESCC development and prognosis, the genetic alterations have not gained clinical applicability.
We applied array-based comparative genomic hybridization (aCGH) to obtain a whole genome
copy number profile relevant for identifying deranged pathways and clinically applicable markers.
Methods: A 32 k aCGH platform was used for high resolution mapping of copy number changes
in 30 stage I-IV ESCC. Potential interdependent alterations and deranged pathways were identified
and copy number changes were correlated to stage, differentiation and survival.
Results: Copy number alterations affected median 19% of the genome and included recurrent
gains of chromosome regions 5p, 7p, 7q, 8q, 10q, 11q, 12p, 14q, 16p, 17p, 19p, 19q, and 20q and
losses of 3p, 5q, 8p, 9p and 11q. High-level amplifications were observed in 30 regions and
recurrently involved 7p11 (EGFR), 11q13 (MYEOV, CCND1, FGF4, FGF3, PPFIA, FAD, TMEM16A, CTTS
and SHANK2) and 11q22 (PDFG). Gain of 7p22.3 predicted nodal metastases and gains of 1p36.32
and 19p13.3 independently predicted poor survival in multivariate analysis.
Conclusion: aCGH profiling verified genetic complexity in ESCC and herein identified imbalances
of multiple central tumorigenic pathways. Distinct gains correlate with clinicopathological variables
and independently predict survival, suggesting clinical applicability of genomic profiling in ESCC.
Background
Esophageal squamous cell carcinoma (ESCC) is a major
cause of cancer-related mortality worldwide. Despite
advances in diagnostic methods and combined treatment
modalities, the majority of the tumors are diagnosed at
advanced stages and the overall 5-year survival rate
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remains 40%. ESCC develops through a multistep process
from dysplasia, through carcinoma in situ to invasive car-
cinoma, and the acquisition of genetic alterations is
tightly related to the dysplasia-carcinoma sequence [1].
The characterization of genetic alterations inherently
linked to ESCC development and an in-depth under-
standing of the molecular mechanisms underlying car-
cinogenesis and growth control may therefore provide
information relevant for early tumor detection, refined
prognosis and development of novel targeted therapeu-
tics.
Loss of heterozygozity (LOH) studies and conventional
comparative genomic hybridization (CGH) analyses have
demonstrated genetic complexity in ESCC and have iden-
tified multiple recurrent copy number alterations, namely
gains of 3q, 5p, 7q, 8q, 11q, 12p, 20p and 20q [2-6].
Amplifications of regions harbouring oncogenes e.g. 7p12
(EGFR), 8q24 (MYC), 17q21 (FGFR) and 11q13 (e.g.
CCND1, FGF4/3, and EMS1)  have consistently been
observed [7-12]. Losses, albeit at a lower frequency than
gains, have recurrently involved 3p, 5q, 9p, 13q, 18q and
21q and include target genes such as FHIT, APC, RB1 and
CDKN2A [3,13-16]. Moreover, some of the changes iden-
tified, e.g. gain of 8q24, 11q13, 12p, and 20q12 and loss
of 3p have been associated with poor prognosis, but
genetic alterations and biological characteristics have so
far had a limited impact on clinical prognostication and
treatment. Taken together, these findings suggest that
genetic profiling can be a useful diagnostic tool in ESCC,
whereas its prognostic role remains uncertain. We used
array-based CGH (aCGH) for high resolution mapping in
30 ESCC and demonstrate that copy number changes
detected by aCGH provide prognostic information
beyond that of classical clinicopathological variables.
Methods
Tumor tissue
All 30 patients, 24 men and 6 women with a mean age of
64 (range 54–78) years, were recruited from the southern
Sweden health care region and had undergone primary
esophagectomy at the Department of Surgery, Lund Uni-
versity Hospital. None of the patients had received neoad-
juvant radiotherapy or chemotherapy. Tumor tissue
collected at surgery was stored at -80°C until DNA extrac-
tion. Stage (according to the International Union Against
Cancer) was I in 3 cases, II in 9, III in 7, and IV in 11 cases
(see Additional file 1). Presence of = 50% tumor cells in
the tissue was verified by touch imprints, which were
stained with Hematoxilin-Eosin and evaluated by a gas-
trointestinal pathologist (B.H.). All deaths were ESCC
related, the median follow up was 21 (range 1–46)
months for the survivors. Written informed consent was
provided by all patients and the study was approved by
the Lund University ethics committee.
BAC Array Platform
We used the 32 k human genome high-resolution BAC re-
arrayed clone set, Version 1.0 from the BACPAC Resource
Center at Children's Hospital Oakland Research Institute,
Oakland (CA, US), produced at the Swegene DNA Micro-
array Resource Center (GEO platform repository acces-
sion GPL4723) [17], Department of Oncology, Lund
University with a resolution >80 kb.
DNA isolation, labelling and hybridization
DNA was extracted, labelled and hybridized as previously
described [17]. A commercial obtained DNA, derived
from a pool of normal human males (Promega, Madison,
WI, USA) was used as reference. Scanning was performed
using an Agilent microarray scanner (Agilent Technolo-
gies, Palo Alto, CA, USA).
Image processing and data analysis
Scanned arrays were analyzed using Gene Pix Pro 4.1
(Axon Instruments, MDS Analytical Technologies,
Ontario, Canada) and bad spots were "flagged" during
manual inspection. The quantified data matrix was loaded
into Bio Array Software Environment (BASE)[18] and fil-
tering and normalization were performed herein [19].
Correction of background intensities of Cy3 and Cy5 were
calculated using median-feature and median-local back-
ground intensities of the uploaded file. Intensity ratios
were calculated from the background tumor channel
(ch1) divided with the reference channel (ch2). Spots
flagged as bad were filtered out from further analysis and
were regarded as missing values. A signal to noise ratio
(SNR) = 5 was set for both channels. Data were normal-
ized using an implementation of a pin-based Lowess algo-
rithm [20] in BASE excluding the X chromosome. A
moving average smoothing algorithm with a 200 kbp slid-
ing window was used and a BASE-adapted CGH-plotter
software was used to identify regions of gains and losses
excluding the X and the Y chromosomes [21]. A region of
gain or loss was defined as two or more consecutive clones
showing an absolute log2 ratio ≥ 0.2 and high-level ampli-
fications as a log2 ratio ≥ 1.5.
Statistical Analysis
A Chi2 test was used to identify differences between copy
number changes and clinicopathological characteristics.
For survival analysis, the Kaplan Meier method was used
to estimate relevant event variables, and the log-rank test
was used to compare survival between two strata. The Cox
proportional hazards model was used for univariate and
multivariate survival analyses. Cox analysis was first used
for all clones, thereafter two or more consecutive signifi-
cant (P < 0.05) clones (interrupted only by one or two
clones) were re-analysed as regions affected by gains and
losses. Regions significantly (P < 0.05) linked to stage/
outcome in univariate analysis were included in the mul-BMC Cancer 2008, 8:98 http://www.biomedcentral.com/1471-2407/8/98
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tivariate analysis. All covariates were evaluated for adher-
ence to the assumption of proportional hazards by
calculating Schoenfeld residuals. Correlations between
changes within a same pathway were analysed using pair-
wise correlation. CGH profiles were classified as gains or
losses according to the dominating variable in the region
corresponding to the gene locus. After Bonferroni correc-
tion correlations with P < 0.05 were considered signifi-
cant. Stata 9.2 (StataCorp LP, College Station, TX 77845,
USA) was used for the statistical calculations.
Immunohistochemical Staining
Serial 4-μm sections from one representative paraffin-
embedded tumor block were used for immunostaining
using a monoclonal antibody against human EGFR at a
dilution of 1:50 (DAKO, Glostrup, Denmark). The slides
were evaluated as no staining; 1+ (cytoplasmic staining or
discontinuous membrane staining); 2+ (membrane stain-
ing with moderate intensity), and 3+ (intense staining
with retained membranous staining). Interpretation of
the staining was performed by two of the authors (AC and
MN), who were blinded to the copy number changes and
the clinical data.
Results
The median number of losses per tumor was 6.9% clones
(range 0.1–24%) and the median number of gained
clones was 9.8% (range 1.1–21%). Recurrent gains identi-
fied in at least 60% of the tumors involved chromosome
regions 5p, 7p, 7q, 8q, 10q, 11q, 12p, 14q, 16p, 17p, 19p,
19q, and 20q. Likely target genes include TERT, EGFR,
MYC, MYEOV, CCND1, FGF4, FGF3, CTTN and AKT1.
Loss of genetic material in at least 40% of the samples
affected 3p, 5q, 8p, 9p and 11q (Table 1). A homozygous
deletion of 9p21.3, corresponding to the CDKN2A locus,
was identified in one case and was verified with PCR using
CDKN2A-specific primers (sequences available from the
authors upon request, data not shown). High-level ampli-
fications were observed in 33 regions and recurrently
involved 11q22 (harbouring PDFG in 3 tumors), 11q13
(in 11 tumors, encompassing MYEOV, CCND1, FGF4,
FGF3, PPFIA, FAD, TMEM16A, CTTS and SHANK2) and
7p11 (including EGFR in 4 tumors). Overexpression of
EGFR was validated by immunohistochemistry, which
revaled a highly positive (3+) staining in 19 tumors, 12 of
which had copy number gain of 7p11. All 4 tumors with
HLA of the EGFR locus showed 2+ or 3+ EGFR staining.
Table 1: Summary of the most frequent copy number gains and losses. Table listing the most frequent copy number gains and losses, 
sorted in decreasing order, in relation to tumor stage. Columns give the cytoband, start reporter, end reporter, size (Mbp), and 
candidate genes in the region.
Cytoband Start reporter End reporter Size (Mbp) Candidate genes
Gains (≥ 60%)
5p15.33 RP11-811I15 CTD-2296H22 1.8 TERT
7p22.3 CTD-2245C5 RP11-745M18 2.3 MAD1L1, NUDT1
7p11.2 RP11-449G3 RP11-535N12 1.1
8q24.13-q24.23 RP11-150N13 RP11-141J23 10.5 MYC, WISP1
8q24.3 CTD-2330C15 CTD-2300I18 1.5 FOXH1
10q26.3 RP13-137A17 RP11-1065F16 0.8
11q13.3-11q13.4 RP11-433A18 RP11-574F24 1.8
12p13.33 CTD-2094C14 RP11-574G8 0.2
14q32.33 CTD-2344P12 RP11-603L1 0.4 AKT1
16p13.3 RP11-344L6 RP11-680M24 3.2
17p13.1 RP11-205D17 RP11-63C7 0.6
19p13.3 RP11-519F9 RP11-81M8 1.6
19q13.42 CTD-2503B7 RP11-528E9 0.3
20q13.33 CTD-2022N11 RP11-350G15 2.4
Losses (≥ 40%)
3p26.3-p24.2 RP11-359E9 RP11-512O18 3.5 RARB, TOP2B
3p14.2-p14.1 RP11-350E21 RP11-175F9 6.9 FHIT
3p14.1-p13 RP11-607B7 RP11-744B4 5.8
5q12.3-q13.1 RP11-158G8 RP11-633F2 0.9 PIK3R1
8p23.2 RP11-46M15 RP11-593J22 2.2
9p24.3-p24.2 RP11-272N16 RP11-778P24 3.1 MTAP, CDKN2A, CDKN2B
9p23 RP11-6H18 RP11-312G1 1.9
9p21.3 RP11-113D19 RP11-16P12 5.2
11q25 RP11-217L21 CTD-2270L17 2.4 ATMBMC Cancer 2008, 8:98 http://www.biomedcentral.com/1471-2407/8/98
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To evaluate whether genes from a same signaling pathway
were correlated, a complementary analysis of pairs of
genomic loci harboring genes (CDKN2A,  MDM2,  RB,
MDM4,  CDKN1A,  PIK3CA,  PTEN,  AKT1,  TP53,  MYC,
CCND1, CCNE1, BCL2, CDK4, E2F3) from central tumor-
igenic pathways was performed. Significant correlations
(P < 0.05) were identified between gain of the MDM4
locus and loss of the RB locus, gain of MDM2 and gain of
TP53, gain of BCL2 and loss of CDKN1A, gain of BCL2
and loss of CDKN2A, gain of CCND1  and loss of
CDKN2A. Significant negative correlations were found
between gain of MDM2  and gain of PIK3CA, gain of
PIK3CA and loss of E2F3, loss of PTEN and gain AKT1,
and concordant gain of AKT1 and gain of CDK4. Pairwise
correlation analysis between members of the EGFR path-
way identified significant (P < 0.05) correlations between
gains of AKT1/HER3, MAPK1/PIK3CA, and MAPK1/AKT1
and between gain of EGFR and loss of PTEN.
Despite genetic complexity (Figure 1), the genomic pro-
files were found to correlate with tumor stage, differentia-
tion, and development of metastases with a lower (mean
13% versus 25%) number of changes in highly differenti-
ated ESCC than in poorly differentiated tumors (see Addi-
tional file 2). A Chi2 test identified ~400 clones that
mapped to 6 genomic regions (2p11.1-2q11.2, 2q35,
3p21.31, 4q12, 4q21.3-4q28.3, 5q12.1) that were signifi-
cantly (P < 0.05) more often found in poorly differenti-
ated tumors. The chromosomal regions most frequently
affected by copy number gains differed between stage I
and stage II-IV tumors. Gains of 6p25.3, 12p13.33 and
17p13.1 were present in all stage I tumors. Stage II-IV
A) Genome-wide frequency plot of DNA copy number gains (red) and losses (green) for all 30 ESCC tumors Figure 1
A) Genome-wide frequency plot of DNA copy number gains (red) and losses (green) for all 30 ESCC tumors. B) 
Genome-wide copy number profile for a Stage I tumor (ESCC 33). Characteristic alterations for a Stage I tumors are gains on 
6p, 12p, and 17p and losses 21q. C) Genome-wide copy number profile for a Stage IV tumor (ESCC 51). Characteristic for 
Stage IV tumors are gains on 12p, 19q and 20q and frequent losses on 3p, 5q and 9p.BMC Cancer 2008, 8:98 http://www.biomedcentral.com/1471-2407/8/98
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tumors showed a higher number of changes, with the
most common gains affecting 12p13.33 (100%), 5p15.33
(85%), 20q13.33 (85%) and 11q13.3 (77%). Overall,
copy number losses were more common in stage II
tumors and the most frequent losses were shared by differ-
ent tumor stages without a significant difference in fre-
quency (see Additional file 3 and 4).
Smaller (pT1) tumors had the lowest number of copy
number changes (mean 12% of the clones affected),
whereas pT2-T4 tumors showed alterations of 27%, 16%,
and 18% of the clones. When gains/losses were correlated
to presence of lymph node metastases, 838 clones that
mapped to 21 genomic regions were identified (see Addi-
tional file 5). Copy number gain in 7p22.3 was signifi-
cantly (P = 0.01) associated with lymph node metastases,
and correctly predicted nodal metastases in 63% of the
patients, as represented by an area under ROC curve of
0.73. Changes in 19 regions, corresponding to 1074
clones, correlated to metastasis at diagnosis (see Addi-
tional file 6) with copy number gain of 8q21.3 being sig-
nificantly associated with the presence of metastasis (P =
0.03). Gain of 8q21.3 could classify 60% of the patients
with distant metastasis with 40% sensitivity and 70% spe-
cificity.
Univariate analysis verified that stage and tumor size were
associated with prognosis; stage HR 1.6, P = 0.04 and pT
HR 1.8, P = 0.05. When copy number gains and losses
were correlated to prognosis, Cox proportional hazards
analysis identified 1284 clones, with a p-value <0.05,
mapping to 30 regions (see Additional file 7). When gains
and losses were separately considered, 7 regions remained
significantly associated to prognosis in univariate analy-
sis. When these regions were entered with stage into mul-
tivariate analysis, gain of 1p36.32 and gain of 19p13.3
independently predicted poor prognosis (Table 2 and Fig-
ure 2).
Discussion
Array-based genomic profiling of ESCC confirms the
genetic complexity suggested by earlier studies that have
applied other means of genetic profiing, e.g. cytogenetics,
conventional CGH, and LOH analysis. We found copy
number gains and losses affecting median 19% of the
genome, identified multiple high-level amplications, and
demonstrated an association between copy number alter-
ations and stage, differentiation and prognosis, suggesting
clinical applicability of genomic profiling in ESCC.
The 11q13 region is central in ESCC development and
alterations herein were identified in 20/31 tumors.
CCND1  is a likely target, but several other candidate
genes, e.g. FGF4, FGF3, CTTN and SHANK2, showed high-
level amplification. This amplicon harboured MYEOV,
which has previously been associated with ESCC and
described to be co-amplified with CCND1 [22]. The RB
pathway is frequently targeted in ESCC carcinogenesis
[23-25] and its activation seems to be dependent mainly
on CCND1 amplification. In our sample set no significant
correlations were observed between the gains/losses
observed in the members of the RB pathway (CCND1,
CCNE1, E2F3 and  CDKN2A). Gain of 14q32.3, which
includes the AKT1 oncogene, was identified in half of the
samples. The PTEN-PIK3CA-AKT signalling cascade is fre-
quently deregulated in several types of cancers and expres-
sion of PIK3CA has been strongly associated with elevated
AKT activity. An increased copy number of PIK3CA is pri-
marily detected in tumors with retained PTEN expression
[26], and indeed, none of the 11 tumors with PIK3CA gain
showed loss of the PTEN  locus at 10q23.3, whereas 7
tumors showed PTEN  loss without change at PIK3CA
locus. The pairwise analysis showed a negative (P = 0.005)
correlation of both copy number gains. Expression data
from array-based oligonucleotide arrays were available
from 8 samples (unpublished data) and verified overex-
pression of PIK3CA in 7 of these tumors, which further
supports PIK3CA and PTEN acting as mutually exclusive
tumorigenic events [27]. Gain of 7p11.2 was identified in
half of the tumors and included high-level amplifications
in 4 tumors. The most likely target gene herein, EGFR, is
overexpressed in a multitude of malignancies and includ-
ing ESCC [7,28-30]. Immunostaining for EGFR was
highly positive (3+) in 12 out of 14 tumors with copy
number gain of EGFR, thus suggesting, as previously
reported [28,31,32], that copy number gain leads to high
Table 2: Regions correlated to prognosis in univariate and 
multivariate Cox analysis. Table listing the regions significantly 
correlated to prognosis in univariate and multivariate analysis. 
Columns give the type of aberration, cytoband, hazard ratio 
(HR), P-value and confidence interval (CI).
A – Univariate Cox analysis
Aberration Cytoband HR P CI
Gain 19p13.3 5.0 0.005 1.6 – 15.5
Gain 3q11.2 6.4 0.012 1.5 – 26.8
Loss 10p11.23 10.3 0.013 1.6 – 65.4
Loss 9q34.3 27.5 0.019 1.7 – 439
Gain 3q22.3 3.7 0.025 1.1 – 11.6
Loss 10q11.21 6.2 0.026 1.2 – 31.1
Gain 1p36.32 3.4 0.030 1.1 – 10.6
B – Multivariate Cox analysis
Aberration Cytoband HR P CI
Gain 1p36.32 19.6 0.005 2.5 – 153.9
Gain 19p13.3 7.0 0.011 1.5 – 31.9
Stage 2.0 0.077 0.9 – 4.4BMC Cancer 2008, 8:98 http://www.biomedcentral.com/1471-2407/8/98
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protein expression in a significant fraction of tumors
(86% in our sample set).
In our cohort, loss of PTEN was observed in 23% of the
samples and was significantly correlated (P  = 0.04) to
EGFR gain, which may be relevant for resistance to EGFR
inhibitors, since PTEN  loss correlates with treatment
resistency. Furthermore, gain of 17q12, harbouring
ERBB2, was observed in 9 tumors and 6 of these showed
concomitant gain of 7p11.2 (EGFR), which suggests that
co-overexpression of ERBB2 and EGFR may apply also to
ESCC [33]. High level amplification of ERBB2 correlated
to overexpression (data not shown). Copy number gain of
5p15 was among the most frequent changes and the min-
imal region of overlap harbour some 20 identified genes,
among which the telomerase regulator TERT, which has
previously been shown to be overexpressed in ESCC and
has been associated with prognosis in other tumor types
[12,34-36]. Gains of 7p22.3, 8q22.3-qter and 20q11.21
were also frequently found and include the target genes
MAD1L1 involved in TERT transcription,  LRP12  and
WISP1 linked to cell survival and p53-mediated apoptosis
and  TPX2  known to activate Aurora-A kinase [37-41].
High-level amplifications affected 33 loci, among which
recurrent high-level amplification peaks were detected at
7p11 (EGFR), 11q22 (cIAP1, MMP3 and PDGF), 11q13
(that harbours e.g. CCND1, FGF4,  FGF3,  CTTN  and
SHANK2), and 10q21 with unknown targets.
The most frequent recurrent copy number losses affected
3p, 5p, 8p, 9p, and 11q, which is consistent with other
studies and these loci also contain several tumor suppres-
sors linked to ESCC [2,3,8,42]. Losses affecting the 9p21-
p24 region, which contains CDKN2A and CDKN2B, were
identified in 13/30 tumors. CDKN2A deletions have been
associated with an invasive and metastatic phenotype and
a homozygous CDKN2A deletion was identified in one
sample [43-45]. Frequent losses were also observed at
3p26-p14 which harbours THRB,  RARB,  TOP2B  and
FHIT. Pairwise correlations between frequently observed
gains and losses identified 5 regions that were signifi-
cantly more often affected by concurrent aberrations. Four
of these were located on the same chromosome, whereas
loss of 3p24 and 5q12 occurred at an increased incidence.
These regions contain targets such as TOP2B, RARB, and
TGFBR2 on 3p and PIK3R1 and RAD17 on 5q, and the
association identified may indicate cross-talk between
genes in these regions.
Conclusion
The accumulation of genetic changes is central in ESCC
development and progression. Our study is the first to
apply high-resolution aCGH to clinical prognostication in
ESCC. Studies that have applied traditional CGH have
suggested a prognostic independent role for genes located
on 8q, 11q, 12p, 14q, and 20q [2,16,46], and a recent
study using a 4k BAC array platform (with 1 Mb resolu-
tion) identified 4 clones, mapping to 3q29, 4q21.21,
8q24 and 8q24.3, linked to survival [47]. The high-resolu-
tion data here presented demonstrates extensive genetic
complexity already in early stage tumors, supports the
involvement of several key genes in ESCC, links gain of
7p22.3 to presence of nodal metastases and demonstrates
that gains of 1p36.32 and 19p13.3 provide independent
prognostic information (HR = 19.6 and 7.0 respectively).
The different prognostic regions identified may be related
to the inherent genetic complexity of ESCC, to differences
in materials (e.g. study populations from different geo-
graphic areas with disparities in dietary and environmen-
Kaplan-Meier survival plots of the two prognostic regions in  multivariate analysis Figure 2
Kaplan-Meier survival plots of the two prognostic 
regions in multivariate analysis. A) Highly significant dif-
ference in survival between patients without gain and with 
gain of 1p36.32 (P = 0.005). B) Difference in survival between 
patients without gain and with gain of 19p13.3 (P = 0.01).BMC Cancer 2008, 8:98 http://www.biomedcentral.com/1471-2407/8/98
Page 7 of 9
(page number not for citation purposes)
tal exposures) and use of different genetic profiling
technologies [48,49]. Nevertheless, these results hold
promise for the application as genetic classifiers and
refined prognostic markers. Moreover, the recognition of
recurrent rearrangements in central signaling pathways
provides a basis for the development of selected and indi-
vidualized targeted therapeutics in ESCC.
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